The EEA1 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal cell carcinoma line. This loss-of-function model features targeted disruption of the EEA1 gene, which encodes the early endosome antigen 1 tethering factor. By eliminating EEA1 expression, these cells enable investigations into endocytic trafficking, receptor signaling, and membrane dynamics without relying on transient suppression methods. The polyclonal format preserves genetic heterogeneity of the edited pool, suitable for population-based assays where clonal biases are minimized, and it represents a reproducible system for functional genomics studies in cancer cell biology.
The host 769-P cell line originates from a primary clear cell adenocarcinoma of the kidney and is widely used as a model for clear cell renal cell carcinoma (ccRCC). These adherent epithelial cells retain key tumor characteristics such as dysregulated hypoxia signaling and metabolic alterations. They are commonly employed to investigate ccRCC tumorigenesis, drug sensitivity, and invasion, while their epithelial phenotype supports studies of endocytic trafficking and receptor sorting in a kidney cancer context.
EEA1 functions as a critical tethering factor for early endosome homotypic fusion, acting as a coincidence detector for both Rab5-GTP and phosphatidylinositol 3-phosphate (PI3P). It is activated by Rab5 GTPases and class III PI3K (PIK3C3)/PI3P, and directly interacts with SNARE components Syntaxin 13 and VAMP8 to mediate endosome docking. EEA1 also binds NSF and Calmodulin, integrating calcium signals into endosomal maturation. Through the Rab5-PI3P-EEA1-NSF-SNARE axis, EEA1 orchestrates endosomal sorting, linking membrane tethering to downstream trafficking decisions such as recycling and degradation.
In renal cell carcinoma, endocytic dysregulation contributes to aberrant receptor tyrosine kinase signaling, migration, and drug resistance. EEA1 knockout in 769-P cells offers a genetic tool to dissect the role of early endosomes in ccRCC. Loss of EEA1 disrupts endosome fusion, potentially altering subcellular distribution of growth factor receptors (e.g., EGFR, MET) and integrins, thereby modulating downstream MAPK, AKT, and mTOR pathways frequently hyperactivated in ccRCC. This model also enables studies of endosomal escape in drug delivery and v-ATPase-dependent acidification relevant to tumor metabolism.
This knockout model supports diverse experimental applications: transferrin and EGF uptake assays for endocytosis kinetics, immunofluorescence and Western blotting for protein localization and expression, co-immunoprecipitation for protein?Cprotein interactions, and RT-qPCR for transcript analysis. Functional assays include cell migration/invasion, phospho-signaling analysis, and drug sensitivity screening for targeted therapies. By disrupting EEA1 in the 769-P background, researchers gain a precise system to investigate endosome-mediated signaling in kidney cancer and beyond. For further information, contact Ascent Research.
